Abstract.
In the past decade, several new antibody-based therapies – using either radiolabelled or unlabelled monoclonal antibodies – have become available for the treatment of patients with refractory or recurrent non-Hodgkin's lymphoma (NHL). Unlabelled monoclonal antibodies (mAbs) kill lymphoma cells by activating host immune effector mechanisms, or by inducing apoptosis. These mAbs can also be used to guide radionuclides to the lymphoma. This radioimmunotherapy (RIT) has been studied with various nuclides (131I, 90Y, 67Cu and 186Re) and with various mAbs. In this review the radionuclides, methods of dosing and recent RIT studies in patients with B-cell NHL are reviewed. Most of these studies demonstrate that RIT is an effective new treatment modality for NHL.
Similar content being viewed by others
Author information
Authors and Affiliations
Additional information
Electronic Publication
Rights and permissions
About this article
Cite this article
Postema, E.J., Boerman, O.C., Oyen, W.J. et al. Radioimmunotherapy of B-cell non-Hodgkin's lymphoma. Eur J Nucl Med 28, 1725–1735 (2001). https://doi.org/10.1007/s002590100570
Published:
Issue Date:
DOI: https://doi.org/10.1007/s002590100570